Literature DB >> 2171718

The pharmacotherapy of focal cortical ischaemia in the mouse.

B Gotti1, J Benavides, E T MacKenzie, B Scatton.   

Abstract

The measurement of cortical omega 3 (peripheral-type benzodiazepine binding) site densities provides an accurate index for the detection and quantification of ischaemic brain lesions following middle cerebral artery occlusion (MCAO) in mice. Here, we have used this marker to assess the neuroprotective activity of potential anti-ischaemic drugs belonging to several chemical classes. In untreated mice, the mean infarcted volume measured 96 h after unilateral coagulation of the middle cerebral artery was 27.9 +/- 4.3 mm3 (17.5% of the hemisphere volume) and omega 3 site densities (measured by incubation with 3H-PK 11195) were increased by 107.3 +/- 4.8% (cortical homogenates) or by 81% (coronal brain sections). The administration of the anti-ischaemic agent SL 82.0715 (10 mg/kg i.p.), 5 min, 6 h and 18 h after the occlusion and then twice daily until sacrifice evoked a decrease of similar magnitude (ca. 60-70%) in the volume of the infarction and in the proliferation of omega 3 sites. The constant tissue sparing effect of SL 82.0715 allowed the examination of the window of therapeutic opportunity. A significant diminution of cortical omega 3 sites was still noted when the first administration was delayed until 3 h post-occlusion. Moreover, the protective effect of SL 82.0715 was enhanced by repeated treatment for the first 36 h but not thereafter. Based on the histological, autoradiographic and homogenate binding results obtained with SL 82.0715, we studied the protective effects of several competitive and non-competitive NMDA receptor antagonists. When administered according to the above-described standard protocol, these drugs reduced omega 3 site levels in cortical homogenates from MCAO mice in a dose-dependent manner. The dose preventing by 50% the increase in omega 3 site levels (in mg/kg i.p.) and the maximal inhibition were respectively: MK-801 (0.2, 93%); TCP (1.6, 66%); kynurenate (260, 58%); ifenprodil (7.0, 58%); SL 82.0715 (1.1, 72%); CGS 19755 (46% at 10 mg/kg); dextromethorphan (46% at 30 mg/kg). In contrast, agents acting preferentially upon sigma (sigma) opiate receptors ((+)-3PPP, 1-10 mg/kg i.p. and haloperidol, 0.3-3 mg/kg i.p.) did not provide a significant protection. In general, calcium channel blockers (nimodipine, flunarizine, verapamil, perhexiline, diltiazem) were devoid of a clear neuroprotective potential when administered at non-toxic doses after the coagulation of the middle cerebral artery. Diltiazem (3 and 10 mg/kg i.p.) provided a significant protection when the first administration was performed 10 min prior to the occlusion. Limited protection was observed with adenosine A1 receptor agonists (N6-cyclohexyladenosine and 2-chloro-adenosine).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2171718     DOI: 10.1016/0006-8993(90)91473-t

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  12 in total

Review 1.  Autoradiographic assessment of the effects of N-methyl-D-aspartate (NMDA) receptor antagonists in vivo.

Authors:  J McCulloch; L L Iversen
Journal:  Neurochem Res       Date:  1991-09       Impact factor: 3.996

2.  Influence of the rate of intravenous administration of eliprodil (SL 82.0715), a new anti-ischaemic agent, on its distribution in rat plasma and tissues.

Authors:  D Garrigou-Gadenne; J P Thenot; P L Morselli
Journal:  J Pharmacokinet Biopharm       Date:  1995-04

3.  The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via sigma1 receptor activation: comparison with the effects of dextromethorphan.

Authors:  Eun-Joo Shin; Seung-Yeol Nah; Won-Ki Kim; Kwang Ho Ko; Wang-Kee Jhoo; Yong-Kwang Lim; Joo Young Cha; Chieh-Fu Chen; Hyoung-Chun Kim
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

4.  Increase in blood-brain barrier permeability, oxidative stress, and activated microglia in a rat model of blast-induced traumatic brain injury.

Authors:  Ryan D Readnower; Mikulas Chavko; Saleena Adeeb; Michael D Conroy; James R Pauly; Richard M McCarron; Patrick G Sullivan
Journal:  J Neurosci Res       Date:  2010-09-29       Impact factor: 4.164

5.  Free radicals and brain damage due to transient middle cerebral artery occlusion: the effect of dimethylthiourea.

Authors:  Y Kiyota; K Pahlmark; H Memezawa; M L Smith; B K Siesjö
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

6.  Neuropathological endpoints in experimental stroke pharmacotherapy: the importance of both early and late evaluation.

Authors:  J Valtysson; L Hillered; P Andiné; H Hagberg; L Persson
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

7.  Blockade by sigma site ligands of high voltage-activated Ca2+ channels in rat and mouse cultured hippocampal pyramidal neurones.

Authors:  J Church; E J Fletcher
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

8.  CGS 19755 (Selfotel): A Novel Neuroprotective Agent Against CNS Injury.

Authors:  Miguel A Pérez-Pinzón; Gary K Steinberg
Journal:  CNS Drug Rev       Date:  1996-09-01

9.  Neuroprotective properties of lifarizine compared with those of other agents in a mouse model of focal cerebral ischaemia.

Authors:  C M Brown; C Calder; C Linton; C Small; B A Kenny; M Spedding; L Patmore
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

Review 10.  Excitatory amino acid antagonists and their potential for the treatment of ischaemic brain damage in man.

Authors:  J McCulloch
Journal:  Br J Clin Pharmacol       Date:  1992-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.